SCHEMBL19667014

SCHEMBL19667014

Cc1cc(O)nc2ccc(NC(=O)c3ccccc3N3CCOCC3)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 5/20 0.57
MAPT P10636 8/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
TP53 P04637 2/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
KDM4E B2RXH2 6/20 0.53
HIF1A Q16665 2/20 0.53
USP2 O75604 1/20 0.53
ALDH1A1 P00352 6/20 0.52
RAB9A P51151 4/20 0.52
HPGD P15428 2/20 0.52
HSD17B10 Q99714 1/20 0.52
NPC1 O15118 3/20 0.52
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479308 0.89 MAPT (0.66) MAPTSMN1; SMN2TP53LMNAMAPK1
SCHEMBL17479091 0.89 ALDH1A1 (0.63) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17479103 0.88 GBA1 (0.54) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17478935 0.88 GBA1 (0.54) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17479284 0.88 GBA1 (0.52) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17478823 0.88 GBA1 (0.52) GBA1MAPTSMN1; SMN2TP53LMNA
SCHEMBL17478615 0.88 GBA1 (0.52) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17478982 0.88 GBA1 (0.52) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17479217 0.86 GBA1 (0.52) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL17478604 0.86 MAPT (0.55) GBA1MAPTSMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106573915-B Compounds active against bromodomains 纽韦卢森公司 2020-12-25 CN claimed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 US claimed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US claimed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS BRD4, BRD3, BRDT GBA1 1736/4885MAPT 575/4885SMN1; SMN2 2459/4885
US-10752640-B2 Compounds active towards bromodomains BRD4, BRD3, BRDT GBA1 1736/4885MAPT 575/4885SMN1; SMN2 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.